Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan

[1]  William M. Lee,et al.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. , 2010, Gastroenterology.

[2]  M. Manns,et al.  Telaprevir for previously treated chronic HCV infection. , 2010, The New England journal of medicine.

[3]  Kristian Thorlund,et al.  Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: Systematic review of randomized trials , 2010, Hepatology.

[4]  T. Mizuno,et al.  Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection , 2009, Journal of viral hepatitis.

[5]  William M. Lee,et al.  CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus , 2010 .

[6]  G. Leandro,et al.  Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. , 2010, Gastroenterology.

[7]  William M. Lee,et al.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.

[8]  Jean-Michel Pawlotsky,et al.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. , 2009, The New England journal of medicine.

[9]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[10]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[11]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[12]  T. Hassanein,et al.  Retreating chronic hepatitis C with daily interferon alfacon‐1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results , 2009, Hepatology.

[13]  E. Schiff,et al.  Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. , 2009, Gastroenterology.

[14]  Yoshiyuki Suzuki,et al.  Effectiveness of combination therapy of splenectomy and long‐term interferon in patients with hepatitis C virus‐related cirrhosis and thrombocytopenia , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[15]  P. Marcellin,et al.  Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-2b , 2009, Annals of Internal Medicine.

[16]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[17]  D. Harnois.  Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection , 2009 .

[18]  T. Toyokawa,et al.  Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[19]  T. Davern.  Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis. , 2008, Journal of clinical gastroenterology.

[20]  D. Bernstein,et al.  Re‐treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon‐alpha‐2a (40 kDa) and ribavirin , 2006, Journal of viral hepatitis.

[21]  N. Hayashi,et al.  Antiviral therapy for chronic hepatitis C: past, present, and future , 2005, Journal of Gastroenterology.

[22]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[23]  M. Manns,et al.  Peginterferon alfa-2b plus ribavirin for chronic hepatitis , 2002, The Lancet.

[24]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .